Quantum Genomics (ALQGC)

Business description

Quantum Genomics is a biopharmaceutical company developing QGC001, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment.

Stock data

Market cap.€34.1m
Last close€3.10
High / Low (52 weeks)€8.1 / €2.9
Stock market listingEU
Forecast net cash (€m)12
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual8.3916(34.1826)(53.7313)
Relative *6.088(35.9776)(61.2585)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
Bonesupport BrainStorm Cell Therapeutics
BTG C4X Discovery Holdings
Can-Fite BioPharma Capstone Therapeutics
Carmat Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Clal Biotechnology Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Collplant Holdings Consort Medical
Corium International Crescendo
Crossject CSL
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
Factor Therapeutics Formycon
Forward Pharma Fresenius SE & Co. KGaA
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genkyotex
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Heat Biologics Inc.
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt Novogen
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Pluristem Therapeutics Prescient Therapeutics
Prima BioMed Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Pharmaceuticals
Race Oncology RedHill Biopharma
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Rovi
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
TESARO Theraclion
Therapix Biosciences Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
Trimel Pharmaceuticals TruScreen Ltd
TxCell UCB
UDG Healthcare uniQure NV
Universal Biosensors VBI Vaccines
Vectura Verastem
Verisante Technology Vernalis
Verona Pharma Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Wilex Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

Quantum Genomics SA (ALQGC) Moves Up 7.37% on Oct 15

Sun, 15 Oct 2017 09:22:30 GMT

Quantum Genomics SA (ALQGC) Declined -0.97% on Oct 20

Fri, 20 Oct 2017 07:18:45 GMT

Biopharma Gets Green Light for Hypertension Study

Thu, 14 Sep 2017 09:09:31 GMT

Quantum Genomics SA (ALQGC) Dips -1.01% on Oct 10

Tue, 10 Oct 2017 11:37:30 GMT

Quantum Genomics SA (ALQGC) Rise 4.44% on Oct 5

Thu, 05 Oct 2017 11:15:00 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2015A 0.1 (4.3) (4.5) (54.70) N/A N/A
2016A 0.0 (6.2) (6.2) (59.79) N/A N/A
2017E 0.0 (8.6) (8.6) (75.96) N/A N/A
2018E 0.0 (10.9) (11.9) (91.00) N/A N/A

Last updated on 05/10/2017

Investment summary

Quantum Genomics recently announced H117 financial results and gave a business update for the first three quarters of the year. It highlighted the results of its Phase IIa trial for QGC001 in hypertension and the launch of the NEW-HOPE study in 250 hypertensive overweight patients across 25 major hospitals in the United States. The company is expecting to complete its 75-patient Phase II study of QGC001 in heart failure by the end of the year, with data expected in H118.

Last updated on 05/10/2017

Industry outlook

The angiotensin pathway is one of the primary methods of modulating blood pressure and it is the target of some of the most successful anti-hypertensive drugs: angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). However, there is a parallel pathway in the brain responsible for the secretion of vasopressin and heart rate that is unaddressed by these classes of drug and that is being targeted by Quantum Genomics.

Last updated on 03/10/2017

Key management

Marc Karako, CFO
Lionel S├ęgard, President and CEO

Company address

Tour Maine Montparnasse
33 Av du Maine
Paris
75015
France
+30 0 1 60 13 76 84
View website